The opportune time for periarticular injection during total hip arthroplasty under general anesthesia: a randomized controlled trial

The opportune time for periarticular injection during total hip arthroplasty under general anesthesia: a randomized controlled trial - The opportune time for periarticular injection during total hip arthroplasty under general anesthesia: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029586

Enrollment

Registered

2017-10-17

Start date

2017-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the hip, rheumatoid arthritis, avascular necrosis of the femoral head, Femoral neck fracture

Interventions

Periarticular injection prior to the arthrotomy and nomal saline injection after the implantation of prosthesis. Nomal saline injection prior to the arthrotomy and periarticular injection injection af

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients scheduled for unilateral total hip arthroplasty

Exclusion criteria

Exclusion criteria: Patients scheduled for simultaneous bilateral total hip arthroplasty. Patients scheduled for revision total hip arthroplasty. Patients scheduled for total hip arthroplasty with shortening subtrochanteric osteotomy. Patients who had allergy or intolerance to one of the study drugs, regular narcotic use, renal insufficiency and prolonged QT interval on ECG.

Design outcomes

Primary

Measure	Time frame
Pain score (Visual analogue scale) at recovery room	—

Secondary

Measure	Time frame
Pain score (Visual analogue scale) 3, 6, 9, 12, 24 and 48 hours after surgery Blood loss Complications The consumption of remifentanil The use of naloxone	—

Countries

Japan

Contacts

Public ContactKenji Kurosaka

Hokusuikai Kinen Hospital Orthopaedic surgery

kenjikurosaka@yahoo.co.jp029-303-3003

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026